Evidence map›Paper›PMID 41212474›Full record

Trial reportTargeted oncology2025

Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung Cancer.

Melissa L Johnson, Shaker R Dakhil, J Thaddeus Beck, Ahad Sadiq, Smitha Menon, Ganesh M Mugundu, Juliann Chmielecki, David R Spigel

2 registry-linked trialsAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Targeted oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02087176 phase2terminatednot on this map

A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 Plus Docetaxel and Placebo Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Patients

TypeinterventionalSponsorAstraZenecaRan2014 to 2015Enrolled48ConditionsPreviously Treated Non Small Cell Lung CancerArmsAZD1775, AZD1775 Placebo, Antimitotic Agent, pegfiligrastim
NCT02087241 phase2terminatednot on this map

A Phase II Study of AZD1775 Plus Pemetrexed and Carboplatin Followed by a Randomised Comparison of Pemetrexed and Carboplatin With or Without AZD1775 in Patients With Previously Untreated Stage IV Non-Squamous Non-Small-Cell Lung Cancer

TypeinterventionalSponsorAstraZenecaRan2014 to 2015Enrolled22ConditionsPreviously Untreated Stage IV Non-Squamous Non Small Cell Lung CancerArmsAZD1775, AZD1775 Matching Placebo, pemetrexed, carboplatin
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Melissa L JohnsonSarah Cannon Research Institute, 1100 Charlotte Ave, Suite 800, Nashville, TN, 37203, USA.ORCID http://orcid.org/0000-0001-9874-1314
Shaker R DakhilCancer Center of Kansas, Wichita, KS, USA.
J Thaddeus BeckHighlands Oncology Group, Fayetteville, AR, USA.
Ahad SadiqFort Wayne Medical Oncology and Hematology, Fort Wayne, IN, USA.
Smitha MenonMedical College of Wisconsin, Milwaukee, WI, USA.
Ganesh M MugunduIMED Biotech Unit, AstraZeneca, Boston, MA, USA.
Juliann ChmieleckiTranslational Science, Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, USA.
David R SpigelSarah Cannon Research Institute, 1100 Charlotte Ave, Suite 800, Nashville, TN, 37203, USA. David.Spigel@SCRI.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdavosertib is a highly selective, small molecule Wee1 inhibitor that sensitizes tumor cells to cytotoxic agents.

objectiveWe report results from the lead-in cohorts of two phase II studies: carboplatin/pemetrexed plus adavosertib versus carboplatin/pemetrexed in first-line metastatic non-squamous non-small-cell lung cancer (NSCLC) (NCT02087241); and docetaxel plus adavosertib versus docetaxel in recurrent NSCLC (NCT02087176). PATIENTS AND

methodsBoth lead-in cohorts assessed early safety and efficacy (objective response rate [ORR]). First-line metastatic treatment was carboplatin (area under the curve to 6 h [AUC

resultsFirst-line: 14 patients were enrolled in four treatment cohorts. Median time on trial was 17.3 weeks, with an ORR of 29%. The most common adverse events were diarrhea (50%), nausea (50%), vomiting (50%), anemia (43%), neutropenia (43%), decreased appetite (43%), and dehydration (43%). Recurrent: 32 patients were enrolled. The ORR was 9%. The most common adverse events were diarrhea (66%), anemia (50%), nausea (47%), fatigue (47%), vomiting (44%), and thrombocytopenia (41%).

conclusionsBoth studies terminated early; the recurrent study after an interim analysis showed increased toxicity and limited efficacy, and the first-line study after a change in first-line standard of care. TRIAL REGISTRATIONS: ClinicalTrials.gov, NCT02087241 and NCT02087176.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsPyrazolesAdultAgedCarboplatinCell Cycle ProteinsDocetaxelFemaleHumansMaleMiddle AgedPemetrexedProtein-Tyrosine KinasesPyrimidinonesadavosertibCarboplatinCell Cycle ProteinsDocetaxelPemetrexedProtein-Tyrosine KinasesPyrazolesPyrimidinonesWEE1 protein, human

Identifiers

PMID41212474
PMCPMC12669328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.